Official Title
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001
Brief Summary
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
No longer available
Individual Patients
Adenomatous Polyposis Coli
Drug: Guselkumab
Guselkumab 100 milligrams (mg) will be administered subcutaneously once every 8 weeks.
Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC
Janssen Research & Development, LLC
NCT Number
MeSH Terms
Colorectal Neoplasms
Nasopharyngeal Neoplasms
Adenomatous Polyposis Coli